BRIEF-Acrivon Therapeutics Reports Positive Endometrial Cancer Data From Ongoing Acr-368 Registrational Intent Phase 2 Study At Esmo

Reuters
2024-09-14

Sept 14 (Reuters) - Acrivon Therapeutics Inc :

* ACRIVON THERAPEUTICS REPORTS POSITIVE ENDOMETRIAL CANCER DATA FROM ONGOING ACR-368 REGISTRATIONAL INTENT PHASE 2 STUDY AT ESMO, ADVANCEMENT OF ACR-2316 INTO CLINIC AHEAD OF TIMELINES, AND PROGRESS ON ITS AP3 INTERACTOME FOR PROPRIETARY DATA ANALYSIS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10